Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.
Danone Nutricia Research, Utrecht, The Netherlands.
Pediatr Allergy Immunol. 2022 Feb;33(2):e13740. doi: 10.1111/pai.13740.
Human milk oligosaccharides (HMOs) have several biological functions. Yet, very few studies have investigated the effect of HMOs on the development of allergies and even fewer on their specific associations with atopic dermatitis (AD) during early childhood.
This study investigated whether individual HMO concentrations, measured at two time points of lactation, were associated with reported diagnosis of AD in children up to two years of age.
Outcome data were available for HMOs measured in human milk samples collected at 6 weeks (n = 534) and 6 months (n = 356) of lactation. Associations of HMOs with AD, ascertained from parents and pediatricians at ages one and two years, were assessed in crude and adjusted logistic regression models.
Few associations were statistically significant at the conventional level (p < .05), for example, 6-week Lacto-N-neotetraose with 2-year AD [OR 95%CI: 0.82 (0.66, 1.00)] and 6-month 3'-sialyllactose among non-secretor mothers with 1-year AD [2.59 (1.53, 6.81)]. Importantly, accounting for multiple testing, these and all further associations were not statistically significant (all p > .0031, which is the threshold for statistical significance after correction for multiple testing).
Our findings suggest that the intake of different levels (or even absence) of the individual HMOs measured at 6 weeks and 6 months of lactation, in the current study, is not significantly associated with the development of AD in early childhood. Given the exploratory nature of our study and the limited sample size, these results should be interpreted with caution. The specific HMOs for which we show plausible associations at conventional level may warrant further research and investigation.
人乳寡糖(HMOs)具有多种生物学功能。然而,很少有研究调查 HMOs 对过敏发展的影响,甚至更少研究它们与婴幼儿特应性皮炎(AD)的具体关联。
本研究调查了在哺乳期的两个时间点测量的个体 HMO 浓度是否与 2 岁以下儿童报告的 AD 诊断有关。
可获得在哺乳期 6 周(n=534)和 6 个月(n=356)采集的人乳样本中 HMO 测量的结果数据。在未经调整和调整的逻辑回归模型中,评估了 HMOs 与 1 岁和 2 岁时父母和儿科医生确定的 AD 的关联。
很少有关联在常规水平(p<0.05)上具有统计学意义,例如,6 周龄的乳-N-新四糖与 2 岁 AD [比值比 95%置信区间:0.82(0.66,1.00)]和非分泌者母亲 6 个月龄的 3'-唾液酸乳糖与 1 岁 AD [2.59(1.53,6.81)]。重要的是,考虑到多次检验,这些以及所有进一步的关联在统计学上均不显著(所有 p>0.0031,这是经过多次检验校正后的统计学显著性阈值)。
我们的研究结果表明,在本研究中,在哺乳期的 6 周和 6 个月测量的不同水平(甚至缺乏)的个体 HMOs 的摄入与婴幼儿早期 AD 的发展没有显著关联。鉴于我们研究的探索性质和有限的样本量,这些结果应谨慎解释。我们在常规水平上显示出合理关联的特定 HMO 可能需要进一步研究和调查。